The DNA methyltransferase DNMT1 and tyrosine-protein kinase KIT cooperatively promote resistance to 5-aza-2′-deoxycytidine (decitabine) and midostaurin (PKC412) in lung cancer cells

Journal of Biological Chemistry

Volumn 290, Issue 30, 2015, Pages 18480-18494

  Yan, Fei ^a   Shen, Na ^a   Pang, Jiuxia ^a   Molina, Julian R ^b   Yang, Ping ^b   Liu, Shujun ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATION; AMINO ACIDS; BIOLOGICAL ORGANS; CELL PROLIFERATION; CELLS; CROSSTALK; CYTOLOGY; DISEASES; DNA; DRUG THERAPY; ENZYMES; GENE EXPRESSION; GENES; METHYLATION; PROTEINS; TUMORS;

CANCER CELL GROWTH; COLONY FORMATION; DNA METHYLTRANSFERASES; DOWN-REGULATION; DRUG RESISTANCE; EPITHELIAL CADHERIN; LUNG CANCER CELLS; TUMOR SUPPRESSOR GENES;

CELL SIGNALING;

DECITABINE; DNA METHYLTRANSFERASE 1; MESSENGER RNA; MIDOSTAURIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE KIT; UNCLASSIFIED DRUG; 4'-N-BENZOYLSTAUROSPORINE; AZACITIDINE; CADHERIN; CDH1 PROTEIN, HUMAN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; STAUROSPORINE; STEM CELL FACTOR RECEPTOR;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CDH1 GENE; CELL COUNT; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG EFFICACY; GENE INACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; AZACITIDINE; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; STAUROSPORINE;

EID: 84937721119     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.633693     Document Type: Article

References (64)

1. Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., Liu, S., Alder, H., Costinean, S., Fernandez-Cymering, C., Volinia, S., Guler, G., Morrison, C. D., Chan, K. K., Marcucci, G., Calin, G. A., Huebner, K., and Croce, C. M. (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U.S.A. 104, 15805-15810
2. Duy, C., Hurtz, C., Shojaee, S., Cerchietti, L., Geng, H., Swaminathan, S., Klemm, L., Kweon, S. M., Nahar, R., Braig, M., Park, E., Kim, Y. M., Hofmann, W. K., Herzog, S., Jumaa, H., Koeffler, H. P., Yu, J. J., Heisterkamp, N., Graeber, T. G., Wu, H., Ye, B. H., Melnick, A., and Müschen, M. (2011) BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 473, 384-388
3. Dufies, M., Jacquel, A., Belhacene, N., Robert, G., Cluzeau, T., Luciano, F., Cassuto, J. P., Raynaud, S., and Auberger, P. (2011) Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget 2, 874-885
4. Easwaran, H., Tsai, H. C., and Baylin, S. B. (2014) Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell 54, 716-727
5. Iliopoulos, D., Guler, G., Han, S. Y., Johnston, D., Druck, T., McCorkell, K. A., Palazzo, J., McCue, P. A., Baffa, R., and Huebner, K. (2005) Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 24, 1625-1633
6. Kurakawa, E., Shimamoto, T., Utsumi, K., Hirano, T., Kato, H., and Ohyashiki, K. (2001) Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer. Int. J. Oncol. 19, 277-281
7. Fabbri, M., Iliopoulos, D., Trapasso, F., Aqeilan, R. I., Cimmino, A., Zanesi, N., Yendamuri, S., Han, S. Y., Amadori, D., Huebner, K., and Croce, C. M. (2005) WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 102, 15611-15616
8. Lin, R. K., Hsu, H. S., Chang, J. W., Chen, C. Y., Chen, J. T., and Wang, Y. C. (2007) Alteration of DNA methyltransferases contributes to 5′CpG methylation and poor prognosis in lung cancer. Lung Cancer 55, 205-213
9. Kim, H., Kwon, Y. M., Kim, J. S., Han, J., Shim, Y. M., Park, J., and Kim, D. H. (2006) Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 107, 1042-1049
10. Shen, N., Yan, F., Pang, J., Wu, L. C., Al-Kali, A., Litzow, M. R., and Liu, S. (2014) A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis. Oncotarget 5, 5494-5509
11. Saito, Y., Kanai, Y., Nakagawa, T., Sakamoto, M., Saito, H., Ishii, H., and Hirohashi, S. (2003) Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int. J. Cancer 105, 527-532
12. Girault, I., Tozlu, S., Lidereau, R., and Bièche, I. (2003) Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin. Cancer Res. 9, 4415-4422
13. Ding, W. J., Fang, J. Y., Chen, X. Y., and Peng, Y. S. (2008) The expression and clinical significance of DNA methyltransferase proteins in human gastric cancer. Dig. Dis. Sci. 53, 2083-2089
14. Etoh, T., Kanai, Y., Ushijima, S., Nakagawa, T., Nakanishi, Y., Sasako, M., Kitano, S., and Hirohashi, S. (2004) Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am. J. Pathol. 164, 689-699
15. Alazzouzi, H., Davalos, V., Kokko, A., Domingo, E., Woerner, S. M., Wilson, A. J., Konrad, L., Laiho, P., Espín, E., Armengol, M., Imai, K., Yamamoto, H., Mariadason, J. M., Gebert, J. F., Aaltonen, L. A., Schwartz, S., Jr., and Arango, D. (2005) Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res. 65, 10170-10173
16. Blum, W., Garzon, R., Klisovic, R. B., Schwind, S., Walker, A., Geyer, S., Liu, S., Havelange, V., Becker, H., Schaaf, L., Mickle, J., Devine, H., Kefauver, C., Devine, S. M., Chan, K. K., Heerema, N. A., Bloomfield, C. D., Grever, M. R., Byrd, J. C., Villalona-Calero, M., Croce, C. M., and Marcucci, G. (2010) Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc. Natl. Acad. Sci. U.S.A. 107, 7473-7478
17. Momparler, R. L. (2013) Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2′-deoxycytidine). Front. Oncol. 3, 188
18. Jüttermann, R., Li, E., and Jaenisch, R. (1994) Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci. U.S.A. 91, 11797-11801
19. Santi, D. V., Norment, A., and Garrett, C. E. (1984) Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc. Natl. Acad. Sci. U.S.A. 81, 6993-6997
20. Müller,C.I.,Rüter,B.,Koeffler,H.P.,andLübbert,M.(2006)DNAhypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. Curr. Pharm. Biotechnol. 7, 315-321
21. Wang, R., Kobayashi, R., and Bishop, J. M. (1996) Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. Proc. Natl. Acad. Sci. U.S.A. 93, 8425-8430
22. Giordano, S., Ponzetto, C., Di Renzo, M. F., Cooper, C. S., and Comoglio, P. M. (1989) Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 339, 155-156
23. Jafri, N. F., Ma, P. C., Maulik, G., and Salgia, R. (2003) Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer. J. Environ. Pathol. Toxicol. Oncol. 22, 147-165
24. Tsuura, Y., Hiraki, H., Watanabe, K., Igarashi, S., Shimamura, K., Fukuda, T., Suzuki, T., and Seito, T. (1994) Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch. 424, 135-141
25. Boldrini, L., Ursino, S., Gisfredi, S., Faviana, P., Donati, V., Camacci, T., Lucchi, M., Mussi, A., Basolo, F., Pingitore, R., and Fontanini, G. (2004) Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin. Cancer Res. 10, 4101-4108
26. Carlomagno, F., and Santoro, M. (2005) Receptor tyrosine kinases as targets for anticancer therapeutics. Curr. Med. Chem. 12, 1773-1781
27. Rossi, A., Maione, P., Colantuoni, G., Ferrara, C., Rossi, E., Guerriero, C., Nicolella, D., Falanga, M., Palazzolo, G., and Gridelli, C. (2009) Recent developments of targeted therapies in the treatment of non-small cell lung cancer. Curr. Drug Discov. Technol. 6, 91-102
28. Ansari, J., Palmer, D. H., Rea, D. W., and Hussain, S. A. (2009) Role of tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med. Chem 9, 569-575
29. Monnerat, C., Henriksson, R., Le Chevalier, T., Novello, S., Berthaud, P., Faivre, S., and Raymond, E. (2004) Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann. Oncol. 15, 316-323
30. Fischer, B., Marinov, M., and Arcaro, A. (2007) Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? Cancer Treat. Rev. 33, 391-406
31. Fabbro, D., Ruetz, S., Bodis, S., Pruschy, M., Csermak, K., Man, A., Campochiaro, P., Wood, J., O'Reilly, T., and Meyer, T. (2000) PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug. Des. 15, 17-28
32. Heinrich, M. C., Blanke, C. D., Druker, B. J., and Corless, C. L. (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 20, 1692-1703
33. Liu, S., Wu, L. C., Pang, J., Santhanam, R., Schwind, S., Wu, Y. Z., Hickey, C. J., Yu, J., Becker, H., Maharry, K., Radmacher, M. D., Li, C., Whitman, S. P., Mishra, A., Stauffer, N., Eiring, A. M., Briesewitz, R., Baiocchi, R. A., Chan, K. K., Paschka, P., Caligiuri, M. A., Byrd, J. C., Croce, C. M., Bloomfield, C. D., Perrotti, D., Garzon, R., and Marcucci, G. (2010) Sp1/NFκB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 17, 333-347
34. Sierra, J. R., Cepero, V., and Giordano, S. (2010) Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol. Cancer 9, 75
35. Lockwood, W. W., Coe, B. P., Williams, A. C., MacAulay, C., and Lam, W. L. (2007) Whole genome tiling path array CGH analysis of segmental copy number alterations in cervical cancer cell lines. Int. J. Cancer 120, 436-443
36. Mishra, M. V., Bisht, K. S., Sun, L., Muldoon-Jacobs, K., Awwad, R., Kaushal, A., Nguyen, P., Huang, L., Pennington, J. D., Markovina, S., Bradbury, C. M., and Gius, D. (2008) DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells. Mol. Cancer Res. 6, 243-249
37. Jelinek, J., Gharibyan, V., Estecio, M. R., Kondo, K., He, R., Chung, W., Lu, Y., Zhang, N., Liang, S., Kantarjian, H. M., Cortes, J. E., and Issa, J. P. (2011) Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One 6, e22110
38. Yan, F., Shen, N., Pang, J., Xie, D., Deng, B., Molina, J. R., Yang, P., and Liu, S. (2014) Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation. Cell Death Dis. 5, e1413
39. Propper, D. J., McDonald, A. C., Man, A., Thavasu, P., Balkwill, F., Braybrooke, J. P., Caponigro, F., Graf, P., Dutreix, C., Blackie, R., Kaye, S. B., Ganesan, T. S., Talbot, D. C., Harris, A. L., and Twelves, C. (2001) Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J. Clin. Oncol. 19, 1485-1492
40. Daskalakis, M., Nguyen, T. T., Nguyen, C., Guldberg, P., Köhler, G., Wijermans, P., Jones, P. A., and Lübbert, M. (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100, 2957-2964
41. Liu, S., Liu, Z., Xie, Z., Pang, J., Yu, J., Lehmann, E., Huynh, L., Vukosavljevic, T., Takeki, M., Klisovic, R. B., Baiocchi, R. A., Blum, W., Porcu, P., Garzon, R., Byrd, J. C., Perrotti, D., Caligiuri, M. A., Chan, K. K., Wu, L. C., and Marcucci, G. (2008) Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-κB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 111, 2364-2373
42. Liu, Z., Liu, S., Xie, Z., Blum, W., Perrotti, D., Paschka, P., Klisovic, R., Byrd, J., Chan, K. K., and Marcucci, G. (2007) Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. Nucleic Acids Res. 35, e31
43. Ohira, T., Gemmill, R. M., Ferguson, K., Kusy, S., Roche, J., Brambilla, E., Zeng, C., Baron, A., Bemis, L., Erickson, P., Wilder, E., Rustgi, A., Kitajewski, J., Gabrielson, E., Bremnes, R., Franklin, W., and Drabkin, H. A. (2003) WNT7a induces E-cadherin in lung cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100, 10429-10434
44. Jiang, L., Chan, J. Y., and Fung, K. P. (2012) Epigenetic loss of CDH1 correlates with multidrug resistance in human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 422, 739-744
45. Wang, Q., Zhou, H. S., Huang, K. K., Jiang, X. J., Wu, F. Q., Cao, R., Yin, C. X., Liao, L. B., Zheng, Z. X., He, H., Lin, R., Yi, Z. S., Xu, D., Yang, M., and Meng, F. Y. (2012) Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia. Int. J. Oncol. 40, 418-426
46. Gleixner, K. V., Mayerhofer, M., Aichberger, K. J., Derdak, S., Sonneck, K., Böhm, A., Gruze, A., Samorapoompichit, P., Manley, P. W., Fabbro, D., Pickl, W. F., Sillaber, C., and Valent, P. (2006) PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107, 752-759
47. Growney, J. D., Clark, J. J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J. D., and Gilliland, D. G. (2005) Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106, 721-724
48. Meissner, A., Gnirke, A., Bell, G. W., Ramsahoye, B., Lander, E. S., and Jaenisch, R. (2005) Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 33, 5868-5877
49. Garzon, R., Liu, S., Fabbri, M., Liu, Z., Heaphy, C. E., Callegari, E., Schwind, S., Pang, J., Yu, J., Muthusamy, N., Havelange, V., Volinia, S., Blum, W., Rush, L. J., Perrotti, D., Andreeff, M., Bloomfield, C. D., Byrd, J. C., Chan, K., Wu, L. C., Croce, C. M., and Marcucci, G. (2009) MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113, 6411-6418
50. Went, P. T., Dirnhofer, S., Bundi, M., Mirlacher, M., Schraml, P., Mangialaio, S., Dimitrijevic, S., Kononen, J., Lugli, A., Simon, R., and Sauter, G. (2004) Prevalence of KIT expression in human tumors. J. Clin. Oncol. 22, 4514-4522
51. Fabbro, D., Buchdunger, E., Wood, J., Mestan, J., Hofmann, F., Ferrari, S., Mett, H., O'Reilly, T., and Meyer, T. (1999) Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol. Ther. 82, 293-301
52. Ikegami, Y., Yano, S., and Nakao, K. (1996) Effects of the new selective protein kinase C inhibitor 4′-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells. Arzneimittelforschung 46, 201-204
53. Courage, C., Budworth, J., and Gescher, A. (1995) Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation. Br. J. Cancer 71, 697-704
54. Tenzer, A., Zingg, D., Rocha, S., Hemmings, B., Fabbro, D., Glanzmann, C., Schubiger, P. A., Bodis, S., and Pruschy, M. (2001) The phosphatidylinositide 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res. 61, 8203-8210
55. Steelman, L. S., Pohnert, S. C., Shelton, J. G., Franklin, R. A., Bertrand, F. E., and McCubrey, J. A. (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18, 189-218
56. Wu, J. J., Zhang, X. D., Gillespie, S., and Hersey, P. (2005) Selection for TRAIL resistance results in melanoma cells with high proliferative potential. FEBS Lett. 579, 1940-1944
57. Weisberg, E., Roesel, J., Bold, G., Furet, P., Jiang, J., Cools, J., Wright, R. D., Nelson, E., Barrett, R., Ray, A., Moreno, D., Hall-Meyers, E., Stone, R., Galinsky, I., Fox, E., Gilliland, G., Daley, J. F., Lazo-Kallanian, S., Kung, A. L., and Griffin, J. D. (2008) Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood 112, 5161-5170
58. Stölzel, F., Steudel, C., Oelschlägel, U., Mohr, B., Koch, S., Ehninger, G., and Thiede, C. (2010) Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells. Ann. Hematol. 89, 653-662
59. Brognard, J., Clark, A. S., Ni, Y., and Dennis, P. A. (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61, 3986-3997
60. Kandasamy, K., and Srivastava, R. K. (2002) Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res. 62, 4929-4937
61. Hopfer, O., Komor, M., Koehler, I. S., Schulze, M., Hoelzer, D., Thiel, E., and Hofmann, W. K. (2007) DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation. Exp. Hematol. 35, 712-723
62. Galmarini, C. M., Mackey, J. R., and Dumontet, C. (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15, 875-890
63. Stam, R. W., den Boer, M. L., Meijerink, J. P., Ebus, M. E., Peters, G. J., Noordhuis, P., Janka-Schaub, G. E., Armstrong, S. A., Korsmeyer, S. J., and Pieters, R. (2003) Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 101, 1270-1276
64. Garcia-Manero, G., Gore, S. D., Cogle, C., Ward, R., Shi, T., Macbeth, K. J., Laille, E., Giordano, H., Sakoian, S., Jabbour, E., Kantarjian, H., and Skikne, B. (2011) Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J. Clin. Oncol. 29, 2521-2527